These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 31259807)

  • 1. PATIENT-REPORTED VISUAL FUNCTION FROM THE OCRIPLASMIN FOR TREATMENT FOR SYMPTOMATIC VITREOMACULAR ADHESION, INCLUDING MACULAR HOLE (OASIS) STUDY.
    Mein C; Dugel PU; Feiner L; Drenser K; Miller D; Benz M; Meunier E; Moro L; Fineman MS
    Retina; 2020 Jul; 40(7):1331-1338. PubMed ID: 31259807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Results of the 2-Year Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) Randomized Trial.
    Dugel PU; Tolentino M; Feiner L; Kozma P; Leroy A
    Ophthalmology; 2016 Oct; 123(10):2232-47. PubMed ID: 27499517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement in Patient-Reported Visual Function After Ocriplasmin for Vitreomacular Adhesion: Results of the Microplasmin for Intravitreous Injection-Traction Release Without Surgical Treatment (MIVI-TRUST) Trials.
    Varma R; Haller JA; Kaiser PK
    JAMA Ophthalmol; 2015 Sep; 133(9):997-1004. PubMed ID: 26068086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Visual function response to ocriplasmin for the treatment of vitreomacular traction and macular hole.
    Jackson TL; Verstraeten T; Duchateau L; Lescrauwaet B
    Acta Ophthalmol; 2017 Dec; 95(8):e740-e745. PubMed ID: 28133919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between anatomical resolution and functional outcomes in the mivi-trust studies using ocriplasmin to treat symptomatic vitreomacular adhesion/vitreomacular traction, including when associated with macular hole.
    Gandorfer A; Benz MS; Haller JA; Stalmans P; Pakola SJ; Girach A; Kampik A; Toth CA; Jaffe GJ;
    Retina; 2015 Jun; 35(6):1151-7. PubMed ID: 25741816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Visual Function Response to Ocriplasmin for the Treatment of Vitreomacular Traction and Macular Hole: The OASIS Study.
    Lescrauwaet B; Duchateau L; Verstraeten T; Jackson TL
    Invest Ophthalmol Vis Sci; 2017 Nov; 58(13):5842-5848. PubMed ID: 29141079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ocriplasmin Treatment Leads to Symptomatic Vitreomacular Adhesion/Vitreomacular Traction Resolution in the Real-World Setting: The Phase IV ORBIT Study.
    Khanani AM; Duker JS; Heier JS; Kaiser PK; Joondeph BC; Kozma P; Rosberger DF; MacCumber M; Boyer DS; Pieramici DJ
    Ophthalmol Retina; 2019 Jan; 3(1):32-41. PubMed ID: 30935657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes.
    Stalmans P; Benz MS; Gandorfer A; Kampik A; Girach A; Pakola S; Haller JA;
    N Engl J Med; 2012 Aug; 367(7):606-15. PubMed ID: 22894573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of Anatomic and Visual Function Outcomes in Patients With Full-Thickness Macular Hole in Ocriplasmin Phase 3 Trials.
    Dugel PU; Regillo C; Eliott D
    Am J Ophthalmol; 2015 Jul; 160(1):94-9.e1. PubMed ID: 25818925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. THE OASIS MP-1 SUBSTUDY: Characterization of the Effect of Ocriplasmin on Microperimetry Parameters.
    Sadda SR; Dugel PU; Gonzalez VH; Meunier E; Kozma P
    Retina; 2019 Feb; 39(2):319-330. PubMed ID: 29206755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ocriplasmin-Induced Macular Hole Closure in the Absence of Vitreomacular Adhesion Release.
    Modi YS; Singh RP
    Ophthalmic Surg Lasers Imaging Retina; 2015 Jun; 46(6):677-9. PubMed ID: 26114851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anatomical and visual outcomes following ocriplasmin treatment for symptomatic vitreomacular traction syndrome.
    Singh RP; Li A; Bedi R; Srivastava S; Sears JE; Ehlers JP; Schachat AP; Kaiser PK
    Br J Ophthalmol; 2014 Mar; 98(3):356-60. PubMed ID: 24357495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-life experience after intravitreal ocriplasmin for vitreomacular traction and macular hole: a spectral-domain optical coherence tomography prospective study.
    Chatziralli I; Theodossiadis G; Parikakis E; Datseris I; Theodossiadis P
    Graefes Arch Clin Exp Ophthalmol; 2016 Feb; 254(2):223-33. PubMed ID: 25940555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Baseline Predictors of Vitreomacular Adhesion/Traction Resolution Following an Intravitreal Injection of Ocriplasmin.
    Jackson TL; Regillo CD; Girach A; Dugel PU;
    Ophthalmic Surg Lasers Imaging Retina; 2016 Aug; 47(8):716-23. PubMed ID: 27548448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EVALUATION OF FULL-FIELD ELECTRORETINOGRAM REDUCTIONS AFTER OCRIPLASMIN TREATMENT: Results of the OASIS Trial ERG Substudy.
    Birch DG; Benz MS; Miller DM; Antoszyk AN; Markoff J; Kozma P; Meunier E; Sergott RC;
    Retina; 2018 Feb; 38(2):364-378. PubMed ID: 28198785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Ocriplasmin as a treatment option for symptomatic vitreomacular traction with and without macular hole. First clinical experiences].
    Maier M; Abraham S; Frank C; Feucht N; Lohmann CP
    Ophthalmologe; 2015 Dec; 112(12):990-4. PubMed ID: 26062717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subfoveal Lucency after Treatment of Vitreomacular Traction without Macular Hole in the Phase 3 Trials of Ocriplasmin Vitreolysis.
    Thomas AS; Folgar FA; Jaffe GJ; Toth CA; Mahmoud TH
    Ophthalmol Retina; 2019 Jan; 3(1):42-52. PubMed ID: 30929816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of Preinjection Spectral Domain Optical Coherence Tomography Findings in the Use of Intravitreal Ocriplasmin in a Clinical Setting.
    Wertheimer C; Haritoglou C; Laubichler P; Wolf A; Kaessmann K; Schumann RG; Priglinger S; Mayer WJ
    Ophthalmologica; 2018; 239(1):11-18. PubMed ID: 28954271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Initial Clinical Experiences Using Ocriplasmin for the Treatment of Vitreomacular Traction with or without a Macular Hole].
    Lenk J; Matthé E; Ventzke S; Pillunat LE; Sandner D
    Klin Monbl Augenheilkd; 2018 Jan; 235(1):73-80. PubMed ID: 28282697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ocriplasmin for symptomatic vitreomacular adhesion.
    Neffendorf JE; Kirthi V; Pringle E; Jackson TL
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD011874. PubMed ID: 29040800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.